Corpus Intelligence IC Memo — THE KINGSTON HOSPITAL 2026-04-26 11:17 UTC
IC Memo — THE KINGSTON HOSPITAL
Investment Committee Memorandum | NY | 147 beds | Grade C | EBITDA uplift $4.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

THE KINGSTON HOSPITAL

CCN 330004 | ULSTER, NY | 147 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

THE KINGSTON HOSPITAL is a 147-bed under-performing / distressed in ULSTER, NY with $65.0M in net patient revenue and a -42.1% operating margin. The hospital serves a payer mix of 48.8% Medicare, 5.3% Medicaid, and 45.9% commercial.

Thesis: Undervalued. Our ML models identify $4.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -42.1% to -34.7% (+736bps).

Net Revenue HCRIS$65.0M
Current EBITDA COMPUTED$-27.3M
Operating Margin COMPUTED-42.1%
Occupancy HCRIS45.1%
Revenue / Bed COMPUTED$442K
Net-to-Gross HCRIS14.1%
Distress Probability ML50.0%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
97
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -42.1% places it below the state median. Among 97 size-comparable peers (74-294 beds), the median margin is -16.4%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (74-294), prioritizing same-state peers. 97 hospitals in the comp set.

HospitalStateBedsRevenueMargin
THE KINGSTON HOSPITAL (Target)NY147$65.0M-42.1%
HOSPITAL FOR SPECIAL SURGERYNY200$1.12B-29.3%
WHITE PLAINS HOSPITALNY292$884.7M8.7%
ROSWELL PARK CANCER INSTITUTENY142$772.3M-40.1%
LINCOLN MEDICAL&MENTAL HEALTH NY287$693.5M-22.9%
QUEENS HOSPITAL CENTERNY200$637.2M4.9%
JAMAICA HOSPITAL MEDICAL CENTENY280$610.4M-18.6%
NYC HEALTH + HOSPITAL / SOUTH NY252$588.5M-16.5%
THE UNITY HOSPITAL OF ROCHESTENY283$571.5M-17.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $4.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.4M+210bp18mo
Cost to Collect4.5%2.5%$1.3M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.3M+198bp12mo
A/R Days Reduction5200.0%3800.0%$791K+122bp9mo
Clean Claim Rate88.0%96.0%$42K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.4M
Cost to Collect
$1.3M
Denial Rate Reduction
$1.3M
A/R Days Reduction
$791K
Clean Claim Rate
$42K
Total EBITDA Uplift$4.8M
Current EBITDA$-27.3M
+ RCM Uplift+$4.8M
Pro Forma EBITDA$-22.5M
Current Margin-42.1%
Pro Forma Margin-34.7%
WC Released (1x)$2.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-42.0M$-132.4M0.00x-100.0%
Base (11x exit)10.0x11.0x$-42.0M$-159.3M0.00x-100.0%
Bull Case9.0x11.0x$-37.8M$-157.2M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-37.8M$-182.6M0.00x-100.0%
Bear Case11.0x10.0x$-46.2M$-142.7M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-46.2M$-171.9M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 97 hospitals with 74-294 beds
  • Same-state prioritization (n=98)
  • Comp margins: P25=-25.8% / P50=-16.4% / P75=-9.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.